Analysts expect LeMaitre Vascular Inc (NASDAQ:LMAT) to report sales of $25.90 million for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for LeMaitre Vascular’s earnings, with the highest sales estimate coming in at $26.12 million and the lowest estimate coming in at $25.60 million. LeMaitre Vascular posted sales of $26.15 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 1%. The company is expected to report its next earnings report on Wednesday, February 20th.

On average, analysts expect that LeMaitre Vascular will report full year sales of $103.08 million for the current fiscal year, with estimates ranging from $102.80 million to $103.30 million. For the next year, analysts expect that the firm will report sales of $110.52 million, with estimates ranging from $109.80 million to $111.30 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Friday, October 5th. The medical instruments supplier reported $0.21 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.21. The business had revenue of $24.17 million for the quarter, compared to analyst estimates of $26.06 million. LeMaitre Vascular had a return on equity of 18.07% and a net margin of 20.52%.

A number of brokerages have weighed in on LMAT. BidaskClub upgraded LeMaitre Vascular from a “sell” rating to a “hold” rating in a research note on Friday, September 28th. Roth Capital cut LeMaitre Vascular from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $38.00 to $39.00 in a report on Tuesday, October 2nd. Zacks Investment Research cut LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Wednesday, September 26th. Barrington Research upgraded LeMaitre Vascular from a “market perform” rating to an “outperform” rating and set a $34.00 price objective for the company in a report on Monday, October 8th. Finally, Canaccord Genuity cut their price objective on LeMaitre Vascular from $40.00 to $32.00 and set a “hold” rating for the company in a report on Monday, October 8th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. LeMaitre Vascular presently has an average rating of “Hold” and an average price target of $35.86.

NASDAQ LMAT traded down $0.59 during trading on Friday, reaching $26.01. The company’s stock had a trading volume of 183,100 shares, compared to its average volume of 146,816. The firm has a market capitalization of $520.88 million, a P/E ratio of 30.70, a P/E/G ratio of 2.17 and a beta of 1.00. LeMaitre Vascular has a one year low of $25.63 and a one year high of $41.28.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 6th. Stockholders of record on Tuesday, November 20th will be issued a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 1.08%. The ex-dividend date is Monday, November 19th. LeMaitre Vascular’s payout ratio is currently 32.56%.

In other news, Director Michael H. Thomas sold 20,000 shares of the company’s stock in a transaction dated Tuesday, October 30th. The stock was sold at an average price of $27.93, for a total value of $558,600.00. Following the completion of the transaction, the director now directly owns 20,000 shares in the company, valued at approximately $558,600. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 20.30% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of LMAT. Vanguard Group Inc. boosted its holdings in LeMaitre Vascular by 5.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,208,742 shares of the medical instruments supplier’s stock valued at $46,826,000 after acquiring an additional 66,427 shares during the period. Legal & General Group Plc boosted its holdings in LeMaitre Vascular by 11.0% during the 3rd quarter. Legal & General Group Plc now owns 33,785 shares of the medical instruments supplier’s stock valued at $1,295,000 after acquiring an additional 3,360 shares during the period. Teachers Advisors LLC boosted its holdings in LeMaitre Vascular by 7.4% during the 3rd quarter. Teachers Advisors LLC now owns 31,470 shares of the medical instruments supplier’s stock valued at $1,219,000 after acquiring an additional 2,162 shares during the period. DF Dent & Co. Inc. boosted its holdings in LeMaitre Vascular by 8.9% during the 3rd quarter. DF Dent & Co. Inc. now owns 25,884 shares of the medical instruments supplier’s stock valued at $1,003,000 after acquiring an additional 2,122 shares during the period. Finally, Summit Global Investments boosted its holdings in LeMaitre Vascular by 10.6% during the 3rd quarter. Summit Global Investments now owns 21,820 shares of the medical instruments supplier’s stock valued at $845,000 after acquiring an additional 2,100 shares during the period. Hedge funds and other institutional investors own 81.54% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Recommended Story: What is insider trading?

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.